12 results about "Pyrrole derivatives" patented technology

The present invention relates to a novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a pharmaceutical composition for potassium-competitive inhibition of gastric acid secretion and a pharmaceutical composition for preventing or treating diseases caused by gastric acid secretion disorder, the pharmaceutical composition containing the novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof as an active component. The pyrrole derivative compound or the like according to the present invention is a potassium-competitive acid blocker (PCAB) and has an excellent H+ / K+ adenosine triphosphatase (ATPase) (proton pump) inhibition effect, and is thus widely used as a therapeutic agent for diseases caused by gastric acid secretion disorder.

This invention relates to the field of pharmaceutical technology, and discloses an atrasentan derivative, its preparation method, and its applications. The atrasentan derivative is a tetrasubstituted pyrrole derivative designed using atrasentan as a lead, significantly reducing the difficulty and cost of synthesis by decreasing three chiral centers. This atrasentan derivative exhibits high safety in HK-2 cells and can significantly improve the pathological state of fibrosis induced by TGF-β in HK-2 cells. It has the potential to be used in the preparation of drugs for the prevention and treatment of renal fibrosis-related diseases, breaking through the synthetic bottleneck of atrasentan and providing a novel candidate drug for the treatment of renal fibrosis.

One embodiment of the present invention provides a semiconductor photoresist composition with excellent resolution characteristics and pattern adhesion by reducing the influence of variables during pattern formation and improving CD (critical dimension) stability. [Solution] The present invention relates to a semiconductor photoresist composition comprising an organometallic compound; a pyrrole-based compound including pyrrole, a pyrrole derivative, or a combination thereof; and a solvent, and a pattern formation method utilizing the same.

This invention discloses a method using arylmethyl ketones and 2-aryl- N This invention relates to a method for synthesizing dihydropyrrole derivatives using toluenesulfonylaziridine as a starting material, belonging to the field of organic synthetic chemistry. The method uses tris(dibenzylacetone)dipalladium (Pd2(dba)3) as a catalyst, and 2-iodobenzoic acid (IBX) and potassium persulfate (K2S2O8) as co-oxidants. N,N Using dimethylformamide (DMF) as both solvent and carbon source, the reaction is carried out in an oil bath at 100℃–120℃ for 15–24 h, followed by post-treatment to obtain dihydropyrrole derivatives. This invention utilizes readily available raw materials, is simple to operate, employs mild reaction conditions, exhibits broad functional group compatibility, provides high product selectivity, and is environmentally friendly. Yields can reach 51%–90%, making it suitable for large-scale preparation of structurally diverse dihydropyrrole derivatives. It has significant application value in drug development, natural product synthesis, and materials chemistry.

The application relates to the technical field of medicines, and discloses application of a tetra-substituted pyrrole derivative in preparation of a product for treating neurodegenerative diseases. The application provides application of the tetra-substituted pyrrole derivative or a pharmaceutically acceptable salt thereof in preparation of the product for treating neurodegenerative diseases. The tetra-substituted pyrrole derivative has high cell safety, and the neuroprotective effect on glutamic acid damage is far higher than that of atrasentan, edaravone and riluzole which are standard clinical drugs; not only can the tetra-substituted pyrrole derivative effectively correct TDP-43 nuclear and cytoplasmic mislocation, but also has the ability of removing insoluble pathological aggregates which atrasentan does not have; the tetra-substituted pyrrole derivative can more effectively inhibit the co-localization of TDP-43 and stress granule protein G3BP1, and intervene in the formation of pathological granules from the source; on a whole animal model, the tetra-substituted pyrrole derivative successfully converts the advantages at the cell level into significant survival benefits, and significantly prolongs the life span of a disease model fruit fly.

The application belongs to the technical field of biological medical materials, and provides a H-aggregated pyrrole derivative, a preparation method and application thereof, the derivative has a molecule with a donor-acceptor (D-A) structure, the donor structure is an aromatic amine derivative, the bridge structure is a dithieno[3,2-b:2,3-d]pyrrole, and the acceptor structure is 2-(3-cyano-4,5,5-trimethylfuran-2(5H)-methylene)malonitrile or 2-[3-cyano-4-methyl-5-phenyl-5-trifluoromethyl-2(5H)-furyl]-malonitrile. Through the synergistic molecular design of "strong donor-large plane bridge-strong acceptor", the application successfully guides the self-assembly of the molecule to form a stable H-aggregate, realizes the "integration" and "synergistic enhancement" of the type I photodynamic and photothermal properties on a single material, and thus can synchronously trigger two kinds of efficient treatment mechanisms under single-wavelength near-infrared light irradiation.

The present application relates to the technical field of pyrrole derivative preparation, in particular to a green preparation method of a compound containing a chiral pyrrole skeleton, and specifically to an L-phenylalanine template compound, which is reacted with 2,5-dimethoxytetrahydrofuran (DMTHF) to obtain a pyrrole derivative directly in water as a green solvent with a high yield, and the scheme is expanded, and an equivalent and easy-to-prepare substitute 1,4-butanediol of DMTHF is used as a starting material and is reacted with L-phenylalaninol to obtain a corresponding amino alcohol pyrrole derivative in a nearly complete quantitative conversion, and the method has the advantages of mild reaction conditions, a green solvent as a reaction medium, nearly complete quantitative conversion, a chiral center configuration maintained, and easy amplification.

This invention discloses a low-temperature, high-speed blow molding method for polylactic acid (PLA) drainage bags, relating to the field of polymer materials technology. The method first involves blending PLA with plasticizers and lubricants, melting and granulating the mixture at a specific low-temperature window, and then blow molding it to obtain a substrate. Subsequently, the substrate is pretreated with a silver ion solution and then subjected to in-situ oxidative polymerization with a dispersion containing functionalized pyrrole derivative monomers and silver phosphate microcapsules loaded with perfluorinated monomers, constructing a composite functional coating on the substrate surface. This invention effectively inhibits the thermal degradation of PLA by strictly controlling the low-temperature process parameters of blow molding, ensuring the safety of the substrate; simultaneously, by embedding microcapsules into the coating through in-situ polymerization, it achieves a synergistic effect of antibacterial and hydrophobic functions.

This invention discloses a carborane derivative, its preparation method, and its applications. Specifically, it involves the reaction of carborane with indole or pyrrole derivatives to prepare carborane-indole / pyrrole quinoxaline compounds. This invention combines a carborane derivative with a 3D structure with a nitrogen-containing heterocyclic quinoxaline with a special 2D electronic structure to obtain compounds with a 3D+2D structure. The synthesis method is simple, mild, and efficient. These compounds avoid aggregation-induced fluorescence quenching caused by 2D structure π-π stacking in the aggregated state, exhibiting good aggregation-induced emission effect. They also have good optical effects, displaying full-color light under 365nm ultraviolet light, and have applications in organic light-emitting materials.

The present disclosure provides a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof. [Chemical formula 1] In chemical formula 1, R1 is an optionally substituted heterocyclic group or an optionally substituted phenyl group, and R2 is an optionally substituted heterocyclic group or an optionally substituted phenyl group.